An international expert panel standardized an indirect immunofluorescence skin biopsy protocol to detect phosphorylated alpha-synuclein, targeting earlier and more reliable diagnosis of synucleinopathies. By aligning sampling and assay details across centers, the protocol aims to reduce variability that has limited clinical confidence in skin-based testing. The move reflects a broader push for reproducible, scalable biomarkers that can support diagnostic differentiation earlier than neurodegenerative progression. Standardization is particularly important for phosphorylated alpha-synuclein, where interpretability depends on consistent tissue processing and immunostaining conditions. The protocol’s release provides a common reference point for clinical labs and future prospective validation studies assessing sensitivity, specificity, and longitudinal predictive value.